FDA Reduces Paperwork for “Compassionate Use”

The change should allow patients with fatal illnesses easier access to experimental drugs, but gaining permission from drug companies remains the biggest challenge.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, VICTORThe US Food and Drug Administration (FDA) has simplified the process by which physicians can obtain experimental drugs for patients with life-threatening illnesses, Kaiser Health News and NPR’s Shots reported today (June 8). Specifically, the required application—which has been tailored to individuals—now has less than half the number of questions, dropping from 26 to just 11. It should now take only 45 minutes to complete, according to the FDA.

Completing the old form was a “pretty laborious process,” Edward Kim, chair of the department of solid tumor oncology at the Carolinas HealthCare System’s Levine Cancer Institute, told Kaiser Health News and NPR.

But whether the new form will improve patient access to such drugs is unclear. Doctors must first get permission from the drug’s maker, and companies may be wary of granting such access for fear that an adverse event could derail the compound’s future development.

“There has been a tendency to focus on this FDA paperwork as the significant part of gaining access to drugs, but where most requests stop is with the company making the drug,” Mark Fleury, a policy analyst at the American Cancer Society Cancer Action Network, told Kaiser Health ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo
Sapio Sciences logo

Sapio Sciences Introduces Biorepository Management Solution